# Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults

> **NCT02165267** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 88 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** VRC01
- **BIOLOGICAL:** SC placebo for VRC01
- **BIOLOGICAL:** IV placebo for VRC01

## Key facts

- **NCT ID:** NCT02165267
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2021-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02165267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02165267, "Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02165267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*